Brief: Windtree Therapeutics Announces Istaroxime Late Breaker Abstract From Its Positive Phase 2 Study In Early Cardiogenic Shock (Seismic) To Be Presented At Heart Failure Society Of America
26/09/2022 14:36
Sept 26 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE THERAPEUTICS ANNOUNCES ISTAROXIME LATE BREAKER
ABSTRACT
FROM ITS POSITIVE PHASE 2 STUDY IN EARLY CARDIOGENIC SHOCK
(SEISMIC) TO BE PRESENTED AT HEART FAILURE SOCIETY OF AMERICA
Source text for Eikon: ID:nGNX83clXt
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study